Preoperative Calcimimetic Treatment may Prevent Serum Creatinine Elevation after Parathyroidectomy in Kidney Transplant Recipients: A Retrospective Cohort Study

Abstract

Background

Hyperparathyroidism (HPT) often persists after successful kidney transplantation (KTx). Although parathyroidectomy (PTx) is an effective treatment option for post-KTx HPT, it is associated with postoperative elevation of serum creatinine levels. We hypothesized that pre-PTx calcimimetic treatment could alleviate the post-PTx increase in serum creatinine levels.

Methods

This retrospective cohort study enrolled KTx patients who underwent initial PTx between 2004 and 2023. Patients’ background characteristics and laboratory data were investigated. The primary outcome was a change in the estimated glomerular filtration rate (eGFR). The cohort was divided into 2 groups based on the presence of pre-PTx calcimimetic treatment. Multivariate linear regression analysis assessed the association between calcimimetic treatment and percent eGFR 1 week after PTx.

Results

Of the 77 KTx patients who underwent PTx, 28 were treated with pre-PTx calcimimetics (calcimimetic group), and the others were not (noncalcimimetic group). Compared with the noncalcimimetic group, the calcimimetic group had lower serum calcium levels before PTx (10.3 vs 11.2 mg/dL, P < .001) and a significantly higher percentage of eGFR 1 week after PTx (95.1% vs 81.5%, P < .001). According to the multivariate analysis, pre-PTx calcimimetic treatment was positively associated with percent eGFR (regression coefficient estimate, 13.76; 95% confidence interval, 7.02-20.50; P < .001) 1 week after PTx.

Conclusion

Pre-PTx calcimimetic treatment may prevent post-PTx elevation of serum creatinine levels in KTx patients.